Analytical testing facility
Alcami has relocated its existing analytical testing facility in Missouri to the Cortex Innovation Center in Central West End, St. Louis.
The old facility has been operational since 1992, with approximately 80 employees. The workforce is expected to reach 125 by 2021.
Alcami announced an investment of $10.7m for the facility’s relocation in February 2017, and construction began in September. Located at 4260 Forest Park Avenue, the new site provides easy access to the company’s domestic and international business partners. It also offers 30% more laboratory space and 14% more stability space.
The new laboratory is intended to perform microbial and chemical analysis, covering raw material and antibiotic testing, drug product release, stability testing, water testing, in-process evaluations, and environmental monitoring for both sterile and non-sterile drugs.
Featuring advanced equipment, the facility will strengthen Alcami’s ability to expand customised services and client-centric innovations for pharmaceutical and biotechnology markets.
In addition to the existing equipment, a wide range of technologies have been installed at Alcami’s new state-of-the-art facility to support development and analytical testing for the drug manufacturing and packaging sectors.
The site incorporates a lab for handling photo-sensitive materials, a low-humidity room for testing and handling hygroscopic materials, pharmaceutical isolators for sterility testing, and ultra performance liquid chromatography (UPLC) equipment for the analysis of drugs.
The laboratory is also equipped with inductively coupled plasma mass spectrometry (ICP-MS) analytical equipment, which allows pharmaceutical companies in their transitions from USP wet chemistry heavy metals.
Alcami’s new analytical testing laboratory occupies the top two floors of a 5,574m² three-storey building in the Cortex Innovation Community complex. This 809,371m² innovation centre promotes bioscience and technology research and development (R&D).
The second floor of the building accommodates a conference room, a large multi-purpose room, 497.5m² of cubicles and office spaces, and a reception area.
The third floor houses sample storage room, a locker room, separate laboratories for chemical and microbiological analysis, lab supervisors, glassware wash and storage areas, and a cleanroom with speciality laboratory areas.
Alcami plans to replace the cleanroom testing equipment with sterility test isolators to reduce the laboratory space.
Headquartered in North Carolina, US, Alcami is engaged in providing customisable services to pharmaceutical and biotechnology companies. With an employee base of 1,000, the company operates seven facilities worldwide.
Alcami offers various technologies for applications including analytical development and testing services, active pharmaceutical ingredients (API) development and manufacturing, formulation development, packaging, solid-state chemistry, and clinical and commercial finished dosage form manufacturing.
Alcami owns two other analytical testing centres in the US, including one in Wilmington, North Carolina, and the other at Edison township in New Jersey.
Lonza has developed a new biomanufacturing complex at its biopark in Visp, Switzerland. Located in Valais, the biomanufacturing complex features…
US-based pharmaceutical company Athenex, in partnership with the State University of New York Polytechnic Institute (SUNY Polytechnic Institute), is building…
In April 2018, China-based biologics services provider WuXi Biologics announced plans to build a biologics drug substance manufacturing facility in…
Fujifilm Diosynth Biotechnologies (FDB), a subsidiary of Japanese multinational conglomerate Fujifilm, is expanding its large-scale biologics production facility in Hillerod,…